Genetic Technologies Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Simon Morriss

Chief executive officer

AU$587.7k

Total compensation

CEO salary percentage	56.2%
CEO tenure	3.3yrs
CEO ownership	n/a
Management average tenure	2.8yrs
Board average tenure	4.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Simon Morriss's remuneration changed compared to Genetic Technologies's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-AU$13m
Sep 30 2023	n/a	n/a	-AU$12m
Jun 30 2023	AU$588k	AU$331k	-AU$12m
Mar 31 2023	n/a	n/a	-AU$10m
Dec 31 2022	n/a	n/a	-AU$9m
Sep 30 2022	n/a	n/a	-AU$8m
Jun 30 2022	AU$629k	AU$347k	-AU$7m
Mar 31 2022	n/a	n/a	-AU$7m
Dec 31 2021	n/a	n/a	-AU$7m
Sep 30 2021	n/a	n/a	-AU$7m
Jun 30 2021	AU$456k	AU$133k	-AU$7m

Compensation vs Market: Simon's total compensation ($USD386.90K) is about average for companies of similar size in the German market ($USD402.64K).

Compensation vs Earnings: Simon's compensation has been consistent with company performance over the past year.

CEO

Simon Morriss

3.3yrs

Tenure

AU$587,744

Compensation

Mr. Simon Morriss, GAICD serves as Chief Executive Officer at Genetic Technologies Limited since February 01, 2021. Mr. Morriss has years’ of experience within the Pharmaceutical, Healthcare and FMCG indus...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Simon Morriss	Chief Executive Officer	3.3yrs	AU$587.74k	no data
Carl Stubbings	Chief Commercial Officer	2.7yrs	AU$296.94k	0.0057% A$ 551.3
Kevin Camilleri	Chief Executive Officer of EasyDNA	2.8yrs	AU$281.15k	no data
Kathryn J. Andrews	CFO & Company Secretary	less than a year	no data	no data
Paul Keith Viney	Consultant	4.8yrs	AU$180.45k	no data

2.8yrs

Average Tenure

Experienced Management: DU8's management team is considered experienced (2.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Lindsay Wakefield	Independent Non-Executive Director	9.7yrs	AU$74.55k	0% A$ 0
Peter Rubinstein	Independent Non-Executive Chairman	6.3yrs	AU$164.72k	2.8% A$ 272.0k
Jerzy Muchnicki	Non-Independent Non-Executive Director	6.3yrs	AU$64.46k	1.7% A$ 165.2k
Finlay Macrae	Member of Scientific & Medical Advisory Board	2.5yrs	no data	no data
Jon Emery	Member of Scientific & Medical Advisory Board	2.5yrs	no data	no data
Ora Gordon	Member of Scientific & Medical Advisory Board	2.5yrs	no data	no data

4.4yrs

Average Tenure

65yo

Average Age

Experienced Board: DU8's board of directors are considered experienced (4.4 years average tenure).

Genetic Technologies Management

Management criteria checks 4/4

Key information

Recent management updates

Genetic Technologies Limited Announces Resignation of Tony Di Pietro as Chief Financial Officer

Genetic Technologies Limited, Annual General Meeting, Nov 22, 2023

Genetic Technologies Limited, Annual General Meeting, Nov 28, 2022

Genetic Technologies Limited Appoints Tony Di Pietro as Chief Financial Officer

Genetic Technologies Limited Announces Resignation of Michael Tonroe as Company Secretary

High number of new and inexperienced directors

Recent updates

Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of $2 million.

New minor risk - Shareholder dilution

Genetic Technologies Limited has filed a Follow-on Equity Offering in the amount of $11.2056 million.

Genetic Technologies Limited has filed a Follow-on Equity Offering in the amount of $2 million.

Genetic Technologies Limited Establishes Clinical Implementation Study with Breast Screen Centres Across New York, Miami and Houston

Genetic Technologies Limited to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare

New major risk - Revenue and earnings growth

Genetic Technologies Limited Announces Resignation of Tony Di Pietro as Chief Financial Officer

Genetic Technologies Regains Compliance with Nasdaq Minimum Bid Price Requirement

New major risk - Market cap size

Genetic Technologies Limited, Annual General Meeting, Nov 22, 2023

Genetic Technologies Limited Announces the Expanded GeneType Multi-Risk Test Is Now Available to Order in Australia

Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2022)

New minor risk - Financial data availability

First half 2023 earnings released: AU$0.001 loss per share (vs AU$0 in 1H 2022)

Genetic Technologies Limited Announces Publication Highlights Genetype’S Ability to Detect Breast Cancer Earlier and Provide Data for Risk Stratification

Genetic Technologies Limited Provides Further Update on Comprehensive Risk Test for Breast & Ovarian Cancer

Genetic Technologies Limited to Launch World’s First Comprehensive Risk Test for Breast & Ovarian Cancer

Genetic Technologies Limited Published in Plus One for Cvd & Type 2 Diabetes

Genetic Technologies Limited, Annual General Meeting, Nov 28, 2022

Genetic Technologies Limited Appoints Tony Di Pietro as Chief Financial Officer

Full year 2022 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2021)

Genetic Technologies Limited (ASX:GTG) completed the acquisition of eCommerce Business and Distribution Rights of AffinityDNA from Affinity DNA Limited.

Genetic Technologies Limited Announces Resignation of Michael Tonroe as Company Secretary

Genetic Technologies Limited Commences Initial Implementation of its geneType Risk Assessment Test at 16 Medical Practices Across the East Coast of Australia

Genetic Technologies Limited Announces the Completion of an Independently Developed and Validated Customisable Budget Impact Model

Genetic Technologies Limited (ASX:GTG) entered into an agreement to acquire eCommerce Business and Distribution Rights of AffinityDNA from Affinity Dna Limited for £0.555 million

Genetic Technologies Limited Announces GeneType Multi-Test Approves for Commercial Release

High number of new and inexperienced directors

Full year 2021 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2020)

Genetic Technologies Limited (ASX:GTG) completed the acquisition of General Genetics Corporation from BelHealth Investment Fund, L.P. managed by BelHealth Investment Partners, LLC.

Company Secretary Justyn Stedwell has left the company

Genetic Technologies Limited Confirms the Launch of GTG's Covid-19 Serious Disease Risk Test (`Covid-19 Risk Test') by US Based Infinity Biologix LLC

Genetic Technologies Limited Provides COVID-19 Risk Test Launch Update

Genetic Technologies Limited Signs 3-Year US Licence Agreement for COVID Risk Test

Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of $6.5625 million.

Genetic Technologies Limited Provides Update on Its COVID-19 Disease Severity Risk Test and Expansion into Germline Testing

Genetic Technologies Limited Announces Management Changes

Genetic Technologies Secures US and ANZ Distribution Rights for PREDICTIX

Genetic Technologies Limited, Annual General Meeting, Dec 10, 2020

Genetic Technologies Limited to Report Q4, 2020 Results on Oct 30, 2020

Full year earnings released - €0.0015 loss per share

Genetic Technologies Provides Update on COVID-19 Risk Test

Full year earnings released - €0.0015 loss per share

Genetic Technologies Receives Delisting Notification Letter from Nasdaq

Full year earnings released - €0.0015 loss per share

Genetic Technologies Regains Compliance with Nasdaq Stockholders Equity Requirement

Full year earnings released - €0.0015 loss per share

Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of $5.125 million.

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age